Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Estrogen Receptor-Positive Breast Carcinoma: early-phase trial registry

6 of 6 indexed Estrogen Receptor-Positive Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 6 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Estrogen Receptor-Positive Breast Carcinoma: 6 US clinical trials tracked, 6 recruiting.

Estrogen Receptor-Positive Breast Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 3 of these trials.

Enrollment posture brief

Registry condition estrogen-receptor-positive-breast-carcinoma

OPEN 6 | RECR 100% | LATE 0 | EARLY 5 | RANK #2866 | SPON 3

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Estrogen Receptor-Positi (th…100%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Estrogen Receptor-Positive Breast Carcinoma

Estrogen Receptor-Positive Breast Carcinoma lists 6 open slots (100% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Estrogen Receptor-Positive Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Estrogen Receptor-Positive Breast Carcinoma is recruiting above its size-band peers.

    6 of 6 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Estrogen Receptor-Positive Breast Carcinoma research.

    Mayo Clinic accounts for 3 of 6 trials (50%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Most Estrogen Receptor-Positive Breast Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.

  4. Estrogen Receptor-Positive Breast Carcinoma research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 25

Phase Distribution

PhaseTrial count
Phase 2 5

Named interventions

Most-linked intervention names on Estrogen Receptor-Positive Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
4 trials
Biospecimen Collection Procedure
3 trials
Placebo Administration Drug
2 trials
Coriolus Versicolor Extract Drug
1 trials
BRC-001 Drug
1 trials
Mushroom Extract Dietary supplement
1 trials
Mammography Procedure
1 trials
F-18 16 Alpha-Fluoroestradiol Drug
1 trials

US sites by state

Facility locations filed on Estrogen Receptor-Positive Breast Carcinoma trials. A trial with sites in several states counts in each.

California 2 trials
Arizona 2 trials
Texas 1 trials
South Carolina 1 trials
Ohio 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Estrogen Receptor-Positive Breast Carcinoma page

6 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 6 Estrogen Receptor-Positive Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Mayo Clinic sponsors the most Estrogen Receptor-Positive Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Estrogen Receptor-Positive Breast Carcinoma condition card totals 6 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.